CGH2466, a combined adenosine receptor antagonist, p38 mitogen‐activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti‐inflammatory activities

No abstract is available for this paper.

• Publication year

  2005

• Venue

  British Journal of Pharmacology

• Publication date

  2005-04-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/sj.bjp.0706132PMID 15685201PMCID PMC1576082
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking.

  2003cited by this paper
• Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.

  2003cited by this paper
• Theophylline: new perspectives for an old drug.

  2003cited by this paper
• In vivo models of lung neutrophil activation. Comparison of mice and hamsters

  2002cited by this paper
• Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities.

  2002cited by this paper
• Adenosine receptor ligands as potential therapeutics in asthma.

  2002cited by this paper
• Evidence for an atypical receptor mediating the augmented bronchoconstrictor response to adenosine induced by allergen challenge in actively sensitized Brown Norway rats

  2002cited by this paper
• Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis.

  2002cited by this paper
• In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.

  2001cited by this paper
• An Overview of the Pharmacokinetics of Cilomilast (Ariflo®), a New, Orally Active Phosphodiesterase 4 Inhibitor, in Healthy Young and Elderly Volunteers

  2001cited by this paper
• Effects of inhibition of PDE4 and TNF‐α on local and remote injuries following ischaemia and reperfusion injury

  2001cited by this paper
• Time course of inflammatory and remodeling events in a murine model of asthma: effect of steroid treatment.

  2000cited by this paper
• Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture.

  2000cited by this paper
• Adenosine receptors and their ligands

  2000cited by this paper
• A COMPARISON OF LOW-DOSE INHALED BUDESONIDE PLUS THEOPHYLLINE AND HIGH-DOSE INHALED BUDESONIDE FOR MODERATE ASTHMA

  2000cited by this paper
• SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.

  2000cited by this paper
• Effect of the p38 kinase inhibitor, SB 203580, on allergic airway inflammation in the rat

  2000influential reference
• Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity.

  2000cited by this paper
• SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.

  2000cited by this paper
• Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism

  2000influential reference
• Species differences in adenosine receptor‐mediated bronchoconstrictor responses

  2000cited by this paper
• The Protein Data Bank

  2000cited by this paper
• p38 MAPK signalling cascades in inflammatory disease.

  1999cited by this paper
• Recent Advances in Our Understanding of the Use of Theophylline in the Treatment of Asthma

  1999influential reference
• Localization and action of adenosine A2a receptors in regions of the brainstem important in cardiovascular control.

  1999cited by this paper
• 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.

  1998cited by this paper
• 1,4‐Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosphodiesterase 4 for the Treatment of Asthma.

  1998cited by this paper
• Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.

  1998influential reference
• Structural basis of inhibitor selectivity in MAP kinases.

  1998cited by this paper
• SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.

  1998cited by this paper
• Adenosine A2B receptors: a novel therapeutic target in asthma?

  1998cited by this paper
• Efficacy and safety of inhaled corticosteroids. New developments.

  1998cited by this paper
• Theophylline and airway inflammation.

  1998influential reference
• Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.

  1998cited by this paper
• Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?

  1997cited by this paper
• A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma.

  1997cited by this paper
• The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase.

  1997cited by this paper
• Current therapies for asthma. Promise and limitations.

  1997cited by this paper
• Activation of A3 adenosine receptors on human eosinophils elevates intracellular calcium.

  1996cited by this paper
• Crystal Structure of p38 Mitogen-activated Protein Kinase*

  1996cited by this paper
• 1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency.

  1996influential reference
• Molecular cloning and functional expression in yeast of a human cAMP‐specific phosphodiesterase subtype (PDE IV‐C)

  1995cited by this paper
• Selective Adenosine-2 Agonist Produces Both Direct and Reflex Tachycardia in Normotensive Rats

  1992influential reference
• Electronic Reprint Biological Crystallography the Protein Data Bank Biological Crystallography the Protein Data Bank

  year unknowncited by this paper

• Selective A3 Adenosine Receptor Antagonist Radioligand for Human and Rodent Species.

  2022cites this paper
• Clinical relevance of understanding mitogen-activated protein kinases involved in asthma

  2020cites this paper
• Discovery of 2-aminoimidazole and 2-amino imidazolyl-thiazoles as non-xanthine human adenosine A3 receptor antagonists: SAR and molecular modeling studies.

  2018cites this paper
• Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases.

  2017cites this paper
• Mitogen‐activated protein kinases as therapeutic targets for asthma

  2017influential citation
• Impact of p38 MAP Kinase Inhibitors on LPS-Induced Release of TNF-α in Whole Blood and Primary Cells from Different Species

  2015cites this paper
• Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats.

  2014cites this paper
• p38β MAP Kinase as a Therapeutic Target for Pancreatic Cancer

  2012cites this paper
• Treatment of allergic asthma: Modulation of Th2 cells and their responses

  2011cites this paper
• New drugs and targets for asthma and COPD

  2010cites this paper
• In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model: a pre-clinical study.

  2010cites this paper
• Chapter 13 Recent Advances in Adenosine Receptor (AR) Ligands in Pulmonary Diseases

  2009cites this paper
• PDE4 inhibitors - a review of the current field.

  2009cites this paper
• Adenosine and adenosine receptors in the pathomechanism and treatment of respiratory diseases.

  2008cites this paper
• Treating COPD with PDE 4 inhibitors

  2007cites this paper
• Agents against cytokine synthesis or receptors.

  2006cites this paper
• The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells

  2006cites this paper
• Are there any realistic chances to develop new drugs for asthma?

  2006cites this paper
• Arachidonic acid pathways in nociception.

  2006cites this paper
• Cytokines as targets in chronic obstructive pulmonary disease.

  2006cites this paper
• Targeting memory Th2 cells for the treatment of allergic asthma.

  2006cites this paper
• Kinase inhibitors and airway inflammation.

  2006cites this paper
• A2B adenosine receptor antagonists and their potential indications

  2006cites this paper
• Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs.

  2006cites this paper